What Half Life Means for Once-Weekly Dosing
The half life of retatrutide is approximately 6 days. That means after each weekly injection, half of the drug is eliminated from the body over the course of those 6 days. By the time the next dose is due on day 7, roughly half the previous dose is still circulating. This creates a steady-state concentration after approximately 4 weeks (the time it takes to reach equilibrium between doses). The 6-day half life is by design — it allows once-weekly dosing while maintaining therapeutic drug levels throughout the week.
How Retatrutide’s Half Life Compares
Retatrutide’s 6-day half life is similar to tirzepatide (5 days) and slightly shorter than semaglutide (7 days). All three drugs use a fatty acid side chain that binds to albumin, which keeps the peptide in circulation much longer than a natural peptide would survive. Without this modification, retatrutide would degrade within minutes. The fatty acid chain — a C18 diacid specifically — is attached to the peptide backbone at a specific lysine residue, and its chain length was optimized during preclinical development to achieve the target half life.
Time to Steady State
Steady state for retatrutide is reached after approximately 4 weeks of weekly dosing. At that point, the drug concentration in the blood stays within a consistent range between doses. This is why the TRIUMPH trial protocols use 4-week intervals for dose escalation — each escalation step allows the body to reach steady state at the new dose level before increasing further. The practical implication is that the first few weeks of treatment show lower drug concentrations and therefore milder side effects, with both efficacy and side effects stabilizing around week 4 at each dose level.
What Happens When You Stop
Because retatrutide has a 6-day half life, it takes approximately 5 half lives — about 30 days — for the drug to be effectively eliminated from the body after the last dose. This is important for two reasons. First, the appetite suppression and gastric slowing effects do not stop immediately when you miss a dose. They fade gradually over 2 to 4 weeks. Second, if you experience intolerable side effects, discontinuing the drug leads to symptom resolution over several weeks rather than immediately. The gradual offset is generally favorable, as it avoids the rebound hunger spike that shorter-acting compounds can cause.
Clinical Implications of the Pharmacokinetics
The 6-day half life means that every 7-day dosing interval maintains drug levels within a narrow peak-to-trough ratio of approximately 2:1. This is a favorable profile — the drug concentration never falls low enough to lose efficacy and never peaks high enough to cause disproportionate side effects. The Phase 2 trial published in the New England Journal of Medicine in 2023 confirmed that this profile produces consistent weight loss throughout the dosing interval with no evidence of end-of-week wearing off.
Leave a Reply